Kurt Brunden, Ph.D., is a professor and director of drug discovery in the Center for Neurodegenerative Research at the University of Pennsylvania, with a research focus in Alzheimer’s disease, Parkinson’s disease and frontotemporal lobar degeneration. Before joining the faculty at the University of Pennsylvania, he was vice president of drug discovery programs in two public biotechnology companies. Prior to that, Kurt was an NIH-funded faculty member at the University of Mississippi Medical Center in the biochemistry department. He received his bachelor’s degree in biology and health chemistry from Western Michigan University and later his doctorate in biochemistry from Purdue University. He then completed a post-doctoral fellowship at the Mayo Clinic.